News

International business leader and philanthropist brings extensive leadership experience, global connections, and a personal commitment to advancing cancer research. The Asian Fund for Cancer Research Limited (AFCR) is pleased to announce the appointment of Mr. Sunil Tuli, Group CEO of King Power…

Imagine being able to detect signs of more than 50 types of cancer through a simple blood test, potentially before symptoms appear. That is the promise of Galleri, a multi-cancer early detection (MCED) blood test developed by GRAIL, a US-based biotechnology company, co-founded…

For patients facing oral cancer, treatment can affect far more than the disease itself. Repeated surgeries may impact the ability to speak, eat, and swallow, making the search for less invasive treatment options especially important. An innovative approach supported by the Asian Fund…

Cancer science is creating new possibilities at an extraordinary pace, but the need for progress continues to grow. In Hong Kong, about 40 people die from cancer every day. Worldwide, approximately one in five people will develop cancer during their…

AFCR's Continuing Commitment to Hong Kong's Biomedical Innovation Ecosystem A Look Back from 2022 to 2026 2022: Asking an Important Question In 2022, the Asian Fund for Cancer Research Limited (AFCR) convened a multidisciplinary Think-Tank Forum at BIOHK around a…

The Asian Fund for Cancer Research Limited (AFCR) will participate in the World Cancer Congress 2026, taking place from 24–26 September 2026 in Hong Kong. Organized by the Union for International Cancer Control (UICC) in collaboration with the Hong Kong Anti-Cancer Society,…

Cell and gene therapies are advancing rapidly. But scientific progress alone is not enough. The next challenge is building the clinical, manufacturing and regulatory systems needed to bring these therapies into wider use safely and effectively, with better outcomes for patients. At the…